Archive for the ‘Scientific & Biotech Conferences: Press Coverage’ Category

Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Nineteen rising stars from Brigham and Women’s Hospital and Massachusetts General Hospital will present in 10-minute sessions.

For a full look at speakers and presentations, please visit the Highlight’s page.

Early career Harvard Medical School investigators kick-off the World Medical Innovation Forum with rapid fire presentations of their high potential new technologies. Nineteen rising stars from Brigham Health and Massachusetts General Hospital will highlight in ten-minute presentations their discoveries and insights that will be the disruptive cardiovascular care of the future. This session is designed for investors, leaders, donors, entrepreneurs and investigators and others who share a passion for identifying emerging high-impact technologies. The top presenter each from BWH and MGH will be awarded the Austen-Braunwald Innovation Prize on Day 2 of the Forum. The prize carries a $10,000 award.

Novel Target Discovery Pipeline for Calcific Aortic Valve Disease
Elena Aikawa, MD, PhD
Director, Heart Valve Translational Research Program, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

Aortic stenosis is a progress of Calcific Aortic Valve Disease (CAVD) – 80,000 patients – sole solution is surgery
Imaging methods for visualization of microcalcification formation: MRI, PET/CT, CAVD Gene network, proteomics heat mapNIRF imaging, microdissection, histology, Tissue layers cells
Serum Sortilin associated with aortic calcification and CVD risk
Discovery pipeline and CAVD Mapping

A zebrafish pipeline for cardiovascular precision medicine
Manu Beerens, PhD
Postdoctoral Research Fellow, Brigham and Women’s Hospital; Harvard Medical School

Cardiomyopathy – group of cardiac disorders: CHF, Atherosclerosis, metabolic syndrome, AF
Zebrafish at the forefront of CVD Precision Medicine
Luciferase activity vs ttn
high throughput screening to identify naxos modifiers
Endpoints: BNP levels Cardiac contractility

Using zebrafish to understand and harness cardiac regeneration

Caroline Burns, PhD
Associate Biologist, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Heart regeneration
Regenerative hearts vs Non-Regenerative hearts
How cardiomyocytes proliferation induced following injury
Uninjured, 1 day after, 7 days after,
Failure to regenerate is related to failure of myoocardial proliferation
Genetic factors required for myocardial proliferation
myocardial proliferation – by Chromatin – mononuclear >4c ploidy
Mononuclear in Human Heart – as research target
How to promote myocardial proliferation
Small molecule as enhanced to drive proliferation

Bioactive Lipid Profiling Can Identify Potential Targets for Altering Life Course Trajectories Toward Cardiometabolic Disease
Susan Cheng, MD
Associate Physician, Brigham and Women’s Hospital, Partners HealthCare; Assistant Professor, Harvard Medical School

Bioactive Lipids
Endogenous and exhaugenous factors
Biochemical intermediates
mechanisms
health and disease outcomes
Small lipid Mediators of Upstream: Eicosanoids and Incidence of Diabetes as Targets for Present and Future
cardiometabolic risk in future early vs late prediabetes, and DM
shared pathways
Statins favoral response
Stree or Injury
Linoleic Acid
Disease and Phynotyping specific investigations
dosing

Small Molecule Predictors of Outcome After Cardiac Interventions
Sammy Elmariah, MD
Assistant in Medicine, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School

Valvular heart disease – elderly, Aortic valve stenosis leads to failure of compensatory ventricular activity of dysfunction
small molecule
fiadnostics biomarkers
Acute kidney injury due to metabolite, adenohomosestine
validate the model – after METABOLITE data is added to the risk classification
Personalizing the timing of Valve Intervention
Biomarkers in blood predicts systolic function, EF,
Metabolite-Driven clinical trial of Aortic stenosis
TAVR

Translational trials in microRNAs
Mark Feinberg, MD
Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

non-coding RNA Biologics – 98% of the genome
2% are coding
MiRNA therapeutics for Atherosclerosis
MiRNA – Replacement Therapy- ApoE-?-NGL
Cholesterol, LDL
Vascular endothelium: Inflammation, HF, Diabetic wound healing – tissue thickness
Example: IncRNA, Example3: miR-26a – BMP-SMAD1-ID1-p21
3 platforms for targeting non-coding RNAs in CVD:

peptide-conjucated nc-RNA
Ab-conjugasted nc-RNA

New approaches to controlling stem cell fate
Yick Fong, PhD
Research Scientist, Brigham and Women’s Hospital; Assistant Professor of Medicine, Harvard Medical School

controlling Stem cell fate by Transcription Factors
Pluripotent, fibroblasts – transformed into Bone, nerve, heart, pancreatic cells
This process is randon and inefficient
GOAL: Transplantation, drug/therapeutic screens
Cellular identity and function
In Vitro Reconstruction of cell-type specific Transcription
Identify Disease mechanism of Heart disease by mutation that cause disruptionCo-regulators disruption

Exercise Prescription to Improve Cardiovascular and Cancer Outcomes in Cancer Survivors
John Groarke, MD
Cardiologist, Brigham and Women’s Hospital; Instructor of Medicine, Harvard Medical

cancer survivers have risk for CVD
Metabolic Equivalent ((METS)
METS is the highest to lower CVD in Cancer survivors
Onco-cardiac rehabilitation
Increase excercise performance vs physical de-conditioned state
Cardioprotection to mitigate CV Toxicities of cancer therapy

Personalizing Diabetic Management with Hemoglobin A1c
John Higgins, MD
Associate Pathologist, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Non glucose factors that affect A1C

RBC Age span – if circulate live longer accumulates more glucose
AstraZeneca, Eli Lilly, Novo Nordics – ALL conduct clinical trials to lower A1C

Personalize DM Management
Using existing assays with the RBC Age adjustment — for achieving better future Outcomes
Device Manufacturers to adjust the device

Characterizing an Early HeartFailure pulmonary EF (HFpEF) Phenotype: Cardiometabolic Disease and Pulmonary Hypertension
Jennifer Ho, MD
Assistant Physician, Massachusetts General Hospital; Member of the Faculty of Medicine, Harvard Medical School

Ejection Frunction in Pulmonary Hypertension (PH)
Obesity >–>>> PH recapitulates human HP
PAECs – Molecular mechanisms – Pulmonary Artery #Endotheline Cells
P13K/Akt (Insulin) — AMPK (Metformin) –>> eNOS — >> Vasodilation
Study ex-vivo PAEC from patients with HFpEF

HFpEF subphenotypes
drug therapy
screening

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Amit Khera, MD
Cardiologist, Massachusetts General Hospital; Instructor, Harvard Medical School

Integration of Genetic data and CVD data
GWAS –>> 60 variants associated with coronary risk
Polygenic genetic risk score
Risk for MI: Genetic risk Interpretation: Monogenic vs Polygenic
High risk comes from polygenic risk: Smoking, Obesity, Excercise, Health diet
Healthy lifestyle “corrects” genetic factor

Monogenic:

Hypercholesterolemia
Trycleceride
increased lipoproteins _ ASA Lp(a) inhibitors

Polygenic

life style, diet excercise
medicationS: Statins

A Novel Epigenetic Complex Implicated in Thoracic Aortic Aneurysm (TAA)
Mark Lindsay, MD, PhD
Physician, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Thoracic Aortic Aneurysm
Aortic dissection
VSCULAR SMOOOTH MUSCLE CELLS in the aorta’s leaves – neo-intima damage vs knockout MALAT1 – nepangiogenesis
GENETIC MUTATIONS as Biologic Probes
GENE: HDAC9 – BRG1, MALAT1 (RNA) – STRESS in aortic homeostasis
Aortic root and Ascending Aorta
Elastin and colagen

Atrial Fibrillation: Genetic Basis and Clinical Implications
Steven Lubitz, MD
Cardiac Electrophysiologist, Massachusetts General Hospital

6 million in US 34 Million WOrldwide
Leading cause of stroke
AF is hard to diagnose
preventable with anticoagulation
AF is Familial and inheritable
Genetic Variation associated with AF – genetics stratified risk
AF Screening: as Stroke prevention – AliveCor
electronic health records are powerful repositories
AF genetic risk – as a Biomarker
Technologies for screening

Targeting Vascular Calcification to Prevent Cardiovascular Disease
Rajeev Malhotra, MD
Staff Cardiologist, Associate Medical Director of the Cardiac Intensive Care Unit, Associate Director of the Cardiopulmonary Exercise Laboratory, Massachusetts General Hospital; Instructor in Medicine, Harvard Medical School

Vascular Classification: Atherocalcification Vascula r disease
plaque destabilization
coronary and aortic
HUMAN GENETICS Studies: GWAS

Genotype
Aortic CT
Identify Potential Genes, increase expression associated with classification
Functional-Mechanical Studies: smooth muscle cell – more proliferative vs more contractile
control vs inhibition
Human model of Vascular classification vs Mouse Model
Disease of Vascular classification: Calxiphylaxis – HEMODialysis patients – >50% mortality within 1 year of diagnosis
Drug development and Clinical Trials

Stratifying Exercise Dysfunction
Bradley Maron, MD
Association Physician, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School

Exercise Dysfunction: Complex Pathophynotype
iCPET: O2, exercise capacity, Pulmonary function, Hemodynamics, Invesive cardiac performance,
NEW SYSTEM DESIGNED: Network-Based Clinical Risk Calculator by Four Clusters – Network determine cluster assignment
Point of care tool – integrate into iCPET
Provides insights into HTN, Valvular, Myocaritis, cardiomyopathy

Pulmonary
exercise capacity
ventilation perf
o2 transport
Invasive cardiac

Novel Mouse Models of Remote Cardioprotection
Benjamin Olenchock, MD, PhD
Cardiovascular Medicine Specialist, Brigham and Women’s Hospital; Instructor in Medicine, Harvard Medical School

Ischemic Preconditing
Remote limb BP Cuff in pig prevented Ischemia in heart
Cell death is multi cell types and cell death
EGLN – succinate +CO2 – Transciptional Hypoxia responses
EGLN Inhibitor: Systemic Egln1 deletion vs Skeletal Muscle Egln1 Deletion – Study of Cardiac Protection
Cardioprotective Mediators: Tissue Hypoxia ++>> Altered hepatic Tryptophan Metabolism —>> Cardioprotection
Tumor xenograph

Harnessing Endogenous Mechanisms of Programmed Gene Expression for Therapeutic Benefit In Cardiometabolic Disorders
Jorge Plutzky, MD
Director, Preventive Cardiology, Cardiovascular Medicine, Brigham and Women’s Hospital

PPARs
RXR, RAR – Retinohyde –>> Retinoic Acid
Transcription factors: Physiology and Pathology
PPARalpha <<<<—- Lipase, Lipid sustrate
Epigenetic Code
Histone Readers: Selective Inhibition of Tumor Oncogenes by DIsruption Enhancing ranked by BRD4 signal: Chemotaxis, adhesion, Migration, Thrombosis, Inflammation
Atherosclerosis: Knows protein, Unknown protein: Promoters, enhancers

Aging and the activin type II receptor pathway: a new target for heart failure therapy?
Jason Roh, MD
Assistant in Medicine, Massachusetts General Hospital; Instructor, Harvard Medical School

AGING and CVD – it is part of pathophysiology – CATABOLIC PROCESSES
Organ level

muscle waist, atropy –>> impaired function: Hand grip strength, walk speed —->> HF, systolic and diastolic Strain rate

Cell level: Isotype Abvs ActRII Ab

contractility, Seen in HF models and HFpEF

Activin-A decreases with AGE

Signaling and pulmonary vascular disease – PAH
Paul Yu, MD, PhD
Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

FIBROSIS: TGF
OSTEOGENESIS ANTI-APOPTOSIS
Activin/TGFBeta —>>> BMP9 (ALK1c)
Loss od signaling
Inflammation
high shear stress
PAH

Idiopathic: Sporadic or heritable
Associated PAH: Scleroderma or lupus

Dysregulated angiogenesis– Anti VEGF165 – Zr-bevacizumab – Using PET-CT

11:30 am – 11:45 am

Break and Move to Discovery Café Breakout

11:45 am – 1:05 pm
7th Floor

Discovery Café Breakout Sessions: Sharing Perspectives

Seven intensive workshops led by our top faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

Topics to be covered include:

Cardiac Replacement Therapy: The Next Ten Years
Heart Failure: Back in The Game through New Pathways
Payment Models: Provider’s Perspective
Molecular Imaging: New Biological Endpoints – Function Over Structure
Open Innovation in Medical Devices: What is it? What Are the Barriers?
Wearables for Cardiovascular Health: How to Validate and Integrate in Care Paths?
Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?

For a full list of speakers, please visit the Highlight’s page.

Seven intensive workshops led by our top faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

Panels

Cardiac Replacement Therapy: The Next Ten Years- Great Republic | 7th Floor

Introducer: Seema Basu, PhD, Market Sector Leader, Partners HealthCare
Garrick Stewart, MD, Associate Physician, Medical Director, Mechanical Circulatory Support Unit, Brigham and Women’s Hospital; Instructor in Medicine, Harvard Medical School
Erin Coglianese, MD, Medical Director, Mechanical Cardiac Support Program, Massachusetts General Hospital

Heart Failure: Back in The Game through New Pathways- Essex North | 3rd Floor

Introducer: Dan Castro, Managing Director, Licensing, Partners HealthCare
Anju Nohria, MD, Director, Cardio-Oncology Program, Cardiovascular Medicine Specialist, Brigham and Women’s Hospital
Christopher Newton-Cheh, MD, Cardiologist, Heart Failure and Transplantation, Massachusetts General Hospital

Payment Models: Provider’s Perspective- North Star | 7th Floor

Introducer: Sepideh Hashemi, Market Sector Leader, Partners HealthCare
Thomas Gaziano, MD, Associate Physician, Cardiovascular Medicine, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School
Jason Wasfy, MD, Assistant Medical Director, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Molecular and Advanced Imaging: New Biological Endpoints – Function Over Structure- Baltic | 7th Floor

Introducer: Glenn Miller, PhD, Market Sector Leader, Partners HealthCare
Marcelo Di Carli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Brigham and Women’s Hospital; Professor of Radiology and Medicine, Harvard Medical School
Farouc Jaffer, MD, PhD, Director, Coronary Intervention, Cardiac Catheterization Laboratory, Cardiology Division, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Sharmila Dorbala, MD, Director, Nuclear Cardiology, Brigham and Women’s Hospital; Associate Professor of Radiology, Harvard Medical School

Open Innovation in Medical Devices: What is it? What Are the Barriers?- Essex South | 3rd Floor

Introducer: Pat Fortune, PhD, Vice President for Market Sectors, Partners HealthCare
Elazer Edelman, MD, PhD, Senior Attending Physician, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School; Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, MIT

Mortality of cardiovascular disease declines as a result of Medical Innovations as Devices
Are innovations tappering off or New ones are coming??

Bruce Rosengard, MD, Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies
Ronald Tompkins, MD, Director, Surgery, Innovation & Bioengineering, Massachusetts General Hospital; Sumner M. Redstone Professor of Surgery, Harvard Medical School

ALL

Solution for Heart Failure – low hanging fruit was picked already – a workabke artificial heart more important than another Stent
Large scale Programs better than multiple PI small grant applications, many are not innovating, conflict of interests, Academia and Industry relations
99% get better with a device but 1% is been harmed
FDA – overworked Underfunded 52 applications reviewed per employee

Wearables for Cardiovascular Health: How to Validate and Integrate in Care Paths?- Parliament/Adams | 7th Floor

Introducer: Thomas Aretz, MD, Vice President, Global Programs, Partners HealthCare
David Levine, MD, Home Hospital Director, Brigham and Women’s Hospital; Fellow in General Internal Medicine, Harvard Medical School
Kamal Jethwani, MD, Senior Director, Connected Health Innovation, Partners HealthCare; Assistant Professor, Dermatology, Harvard Medical School
Paolo Bonato, PhD, Director, Motion Analysis Laboratory, Spaulding Hospital; Associate Professor, Harvard Medical School

Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why? Empire | 7th Floor

Introducer: Trung Do, Vice President, Business Development, Partners HealthCare
George Washko, MD, Associate Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School
Mark Michalski, MD, Director, CCDS, Brigham and Women’s Hospital, Massachusetts General Hospital

1:05 pm – 1:30 pm

Break

1:30 pm – 1:35 pm
Boston Scientific Ballroom

Opening Remarks Christopher Coburn

Introduction by: Anne Klibanski, MD,

Chief Academic Officer, Partners HealthCare
Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School

David Torchiana, MD

CEO, Partners HealthCare

1:35 pm – 1:55 pm
Boston Scientific Ballroom

Reinventing Cardiac Care

Two renowned clinical leaders provide an overview of the medical and economic challenges that cardiovascular and cardiometabolic disorders present.

They will highlight strategic direction in cardiac research and clinical care at Partners, and address how recent trends in investment, regulation, and policy may be dovetailed with efforts at Partners.

The experts also spotlight for attendees the various therapies, diagnostics, devices, and critical issues that will be discussed throughout the upcoming 2.5 days of the World Medical Innovation Forum.

Calum MacRae, MD, PhD

Chief of Cardiovascular Medicine, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School

New drugs: Molecular targets, Monoclonals, alternative to Statins
devices implantable
IT and EMR, BI
Integration of Innovations, Clinical and Translational

Anthony Rosenzweig, MD

Chief, Cardiology Division, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School

Aging and longevity of CVD Patients will increase the expense on CVD as disease

1:55 pm – 2:45 pm
Boston Scientific Ballroom

CEO Roundtable: Today’s Learning, Tomorrow’s Opportunities

Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.

Moderator: Benjamin Pless

Executive in Residence, Partners HealthCare Innovation

Electrical physiology: implantable paceamker – first 1958, lead to RV, last 10years th enetire pacemaker implanted in the heart no leads. Surgical TAVR, Implantabke to Mitral valve

John Flannery

CEO, GE Healthcare

Healthcare data, Analytics, data integration, machine learning, mapping efficiency,
Data analytics is Present, Devices was the Past
Shorten cycle of learning

Michael Minogue

CEO, Abiomed

20X of revenue growth since 2010
HEART PUMP – only FDA approached for recover the heart, pump blood out of the heart
Tracking ALL patients not samples – ALL Outcomes, all patients
HF – 24×7 employees of Abiomed in labs in Hospitals, 5 years after heart attack, another attack 30% dies
Protocol and standards

Michael Mussallem

CEO, Edwards Lifesciences

TAVR device no need for open heart surgery
Selling services – heart-lung machine: Perfusion is a product and Service
Structural heart disease – multiple innovations

Timothy Ring

CEO, Bard

Oncology, Vascular, Urology, PDA
Business model failure – clinical economic point of view
Start up community and acquisitions – platforms for further investments

Lewis Sandy, MD

EVP, Clinical Advancement, UnitedHealth Group – Payer’s perspective

Health Benefits
Optum – Data to improve care,
30% of cost of care is WASTE, eliminate this cost item
Heart transfer: Innvation cycle
Collaboration with Pharma and with Devices: Data Analytics – fee for service vs Value Model – Total cost may be less

2:45 pm – 3:35 pm
Boston Scientific Ballroom

Tackling the AFib Epidemic

Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.

Moderator: Jagmeet Singh, MD, DPhil

Associate Chief, Cardiology Division, Massachusetts General Hospital Heart Center
Professor of Medicine, Harvard Medical School

HF treated by five drugs
3Million Patients in 2050 20Million Patients to experience HF
Heart Rate – Rythm control in normal renge
ablation surgery
Prevention of Strokes
AF: Chronic, persistent
Risk is transferred to the providers
Genetic profiling for early detection
Going upstream for the Genetics and the Prevention

Patrick Ellinor, MD, PhD

Director, Cardiac Arrhythmia Service, Massachusetts General Hospital
Associate Professor, Harvard Medical School

AF in Men with Prostate Cancer and Women with Breast Cancer
Pathological issues
Cardiovergent or not
poor definition of the AF underpinning
NEW type of anticoagulation Safer that Warfrin
2/3 of AF are not on anticoagulation: Patient preference, doctor preference related to intolerance
Screening AF with Genetics

Colleen Fowler

VP, GM, AF Solutions, Medtronic

AF 26Billion spend in the Hospitals
Outcome improvement
Lowering AF burden is very beneficial – endpoint of freedom of 30 seconds of AF for patient with comorbidities
AF – multiple CV diseases
Identify AF earlier – US not labeled product for AF Patient, outcome data needed
drug management – which patient will benefit: help only patients that will benefit not any patient
Wholistic view of AF

Parashar Patel

VP, Global Health Policy, Boston Scientific

Payment reduction,
Chronic condition with Acute episodes, post procedure
life style modification
Benefits last 3 years, then they come back
Payers and MDs will ask for changes in life style for chance of success [weight reduction reached to qualify for knee replacement]
Frint end and backend improvement – room to be optimistic

Michael Rousseau

President, Cardiovascular and Neuromodulation, Abbott

AF – inprovement of Patient quality of life
extended patient life
Innovation solutions : Improve Clinical outcomens and cost care reduction final Goal: CURE
Each patient need the entire Tool Box creation of multiple tools
Devices – how is the value determined? value delivered along a time span not insinq with cost
Innovation in patient active participation in health management – tracking by Step,
Incremental innovations

Steven Zelenkofske, DO

VP US Medical Affairs, CVMD TA, AstraZeneca

Drugs for AF, biology of the disease little advancement, durg approach – understand the biology of the disease and streamline approach
Disease progresses, remission,
Is there a Biomarker as predictor for development of AF? delay onset of AF
HTN is a potential cause of AF not in all cases
Sleep Apnea, life style predictors of AF
Drugs do not work have high toxicity for Arrhythmia 50% reduction in AF 25% placibo reduction – wrong target – Channels is not the right target
Genomics and Biology — need to understand the disease better

3:35 pm – 4:05 pm
Boston Scientific Ballroom

1:1 Fireside Chat: Omar Ishrak, PhD, CEO, Medtronic

Moderator: Paul LaViolette

Managing Partner & COO, SV Life Sciences Advisers

Technology and Value
M&A
Disease pathway

Omar Ishrak, PhD

CEO, Medtronic

Innovations are the essence of Medical Devices development as mission in technology
Training Challenge in Surgical Robotic – patient comfort of minimal invasive therapy, cost lower
Antibacterial sleeve saves cost of hospitalization, id infection occur Medtronic reimburses Hospital
Respect of NOT INVENTED HERE – internal and external
M&A 0 TAVR internal development THEN acquisition, HTN – acquisition did not work
DIABETIC PUMP – investment in R&D over 15 years
Care management as Services – therapy and care management
Technology company paid when it is delivered: understand cohorts,
Strategy: Chronic Disease: AF, ablation is needed –
Strategy: episodic care – success of intervention and the recovery from acuity, HF compensation in early stageCRT – hospitalization one year after the intervention is not acceptable
9 and 10 are measuring outcome differently
Mitral Valve – platform for new generation of diagnostics
ETERNAL: recover fast, improve outcome

4:05 pm – 4:55 pm
Boston Scientific Ballroom

Heart Failure’s Therapeutic Mandate

One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.

Moderator: Akshay Desai, MD

Director, Heart Failure Disease Management, Brigham and Women’s Hospital
Associate Professor, Harvard Medical School

How to leverage Big data
Need for new therapies – collaboration of Academia and Pharma and Hospital

Philip Adamson, MD

VP and Medical Director, Abbott

HF – number of patient will double as Population grows and ages
Pharmacogenetics will explain the pathophysiology
Longterm management by specialist is important vs by PCP
How do we randomize trials
REIMBURSEMENT is key
Glory of being persistant

Craig Basson, MD, PhD

VP, Global Translational Medicine Head (CVM), Novartis Institutes for BioMedical Research
Senior Lecturer, Harvard Medical School

HF – lags behind
heterogenous disease
Preserve EF
Genomics data collected on large population
Big data is here, genotype, phynotypes, – high quality data sets translation od data to therapeutics is coming
Biomarkers important for endpoints
Impresco – HF Drug with 20% improvement in EF

Marc Semigran, MD

CMO, Myokardia

HF – genetic and cellular level needed – in Oncology this is basic
Precision medicine requires, devices to download CMR Cardiovascular magnetic resonance imaging (CMR), – data on fibrotics
diagnosis etiology of HF is complex
Preclinical trials are very important for early insights
Younger patient with cardiomiopaty and older patient

Kenneth Stein, MD

SVP, CMO, Global Health Policy, Rhythm Management, Boston Scientific

CHF is s clinical Syndrome,
Telemeter physiologic information
Physiology of HF – is well understood vs AF
Translation of pathophysiology to therapeutics NOT YET accomplished
Impending HF – device better that BP by MS
Combination of therapies – what strategies yield best outcome, 20,000 participants in Clinical Trials is the wrong practice
Translational science fails when clinical trials fail
Need to be in the long haul, there is a model to be successful

4:55 pm – 6:00 pm
Boston Scientific Ballroom

CLINICAL HIGHLIGHT: A New Chapter of PAD

PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.

The panel will also discuss, Below The Knee: The Persisting Unmet Need

Moderator: Michael Jaff, DO

President, Newton-Wellesley Hospital, Partners Healthcare
Professor of Medicine, Harvard Medical School

Reimbursement strategy for PAD
Congratulate CMS for covering PAD
Clinical Trial design for devices for PAD – limitations as to what to propose to FDA and CMS

Douglas Drachman, MD

Director, Cardiology and Interventional Cardiology Fellowship Programs, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School

Nine million patient PAD
systemic therapy, early access to care, arterial insufficiancy, better vascularization
Modification diet for atherosclerotic disease – Mediterranean diet – conselling patients on a regular basis
training operator – baloons is a game changer
durable patency – no need to go back
systemic burden od atherosclerosis
Public recognition of PAD as an important complex disease

Tamara Syrek Jensen

Director, Coverage and Analysis Group, CMS

coverage incentives in the payment system
design trials with FDA and CMS to ensure approval and reimbursement – know early
Evidence-based tool, quality measure group
CMS approach for site of treatment/service so to be reimbursed
“Reasonable and Necessary” definition for PAD treatment – CMS continue to be innovative
CMS needs data to cover technology
CMS wishes to work with MDs

Misti Malone, PhD

Chief, Peripheral Interventional Devices Branch, Food and Drug Administration

heterogeneity, lack of data
devices approval require consistent data, collaboration with NIH, CMS – design meaningful trials
Match patients and match treatment
mulriple companies work with FDA – FDA is willing to accept treatment, benefit and the labeling claims
Early contacting FDA

Shaden Marzouk, MD

CMO, Cardinal Health

neuronal claudication vs vascular claudication
continnum of care

Matthew Menard, MD

Co-Director, Endovascular Surgery, Brigham and Women’s Hospital
Assistant Professor, Harvard Medical School
Critical Limb Ischemia (CLI)
3D Printing – morphologic information on density and on patency
PAD is a tremendous challlenge PCI was solved PAD not yet

Jeff Mirviss

SVP and President, Peripheral Interventions, Boston Scientific

ANTI peripheral therapies – above the knee and below the knee – different vessels
No Consistency in wound care across institutions – complexity on top of complexity
Balance of rigorous science with adjustment by FDA
Strategy – Category Leadership: not a singular technology: Bare stent, Stant and baloon and drug eluting stent
PAD atherectomy
Stem cells harvesting for clinical Trial – early stage research to assist patient early rather at late stage
PAD Options is evolving

6:00 pm – 6:45 pm
Lilly Foyer

Opening Reception

Read Full Post »

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Posted in Cancer and Current Therapeutics, Conference Coverage with Social Media, Scientific & Biotech Conferences: Press Coverage on March 13, 2017| Leave a Comment »

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

REAL TIME PRESS COVERAGE & Reporter: Aviva Lev-Ari, PhD, RN

Summer Symposium 2017

https://ki.mit.edu/news/symposium/2017

@kochinstitute #KIsymposium @Pharma_BI @AVIVA1950

A leader in Convergence, MIT’s Koch Institute for Integrative Cancer Research will, on June 16, present its 16th annual Summer Symposium: the Convergence of Science and Engineering in Cancer Research. Convergence—the merging of historically distinct disciplines such as engineering, physics, computer science, chemistry, mathematics, and the life sciences—has created extraordinary opportunities in cancer research and care. Leaders in this emerging field will discuss innovative new approaches and technologies to better detect, monitor, treat, and prevent cancer. The symposium will also feature a panel of experts to discuss the impact of Convergence on the future of medical care.

INTRODUCTORY REMARKS

Tyler Jacks, PhD
Director, Koch Institute, MIT
David H. Koch Professor of Biology, MITLIVE – new Solutions for Cancer the mission og KI. Sponsors: Affiliates, Collaborators, Patrons, Friends, Vendors. Introduction to Prof. Sharp. 40th Anniversary of RNA related discovery leading to Nobel Prize of Prof. Sharp.

Concluding the Symposium

continum
June 15, 2018 – NanoMedicine
Fall Symposium in September 2017

Phillip A. Sharp, PhD
Institute Professor, MIT
Koch Institute, MIT

LIVE – Convergence of Science and Engineering. Key note by a convergent personality – Eric Lander.

Convergence is a blueprint for innovation – NOW transformation of Life Science that follows the transformation of Physical sccience. Molecular biology – Delbruck, transmission of genetic phenotypes. Revolution of Biological Sciences in 20th Century

1st Revolution – DNA Structure, 1953

2nd Revolution – genomics Human Genome 2003

3rd Revolution – Integration of Science and the Environment in 21st Century

Such Small investment, 3.4% of NI Funding went to PI in BioEngineering 2000-2016

Introduction to Eric Lander – 1986 – to Whitehead Institute and MIT, now at Broad

KEYNOTE SPEAKER

30 Years of Convergence

Eric Lander, PhD
President and Founding Director, Broad Institute of Harvard and MIT
Professor of Biology, Department of Biology, MIT
Koch Institute, MIT
Professor of Systems Biology, Harvard Medical School

LIVE – Personal Reflection on Convergence in BioMedicine

Process is important inconvergence — WHAT ARE WE CONVERGING TOWARD?

1985 — today — 2045

BioMedicine – born from 4 Intellectual Revolutions:

Biochemistry – since 1890
Genetics – since 1900
Molecular Biology – since 1945, 1953, 2003
Recombinant DNA – since 1970

GENOMICS comes along: a View of

Completeness, Nature, 1986 – before the flood of data

Biology is Finite – systematically perturbed
Proteomics

Comprehensive views

Discovering Disease Genes – 1980s: Mendelian rare inherited, Common variation, Somatic

Human Genome – Finished, 2003
DNA, RNA, Proteins (Kinase, E3 Ligase) are finite and can be recognized from signatures

Human Genome Variations

Discovering Disease Genes – 2000s:

2017: 100 diseases are derived from Genome variation

Disease Pathways discovered systematically: schesophrenia
Cancer – Chromatin regulators and remodelers
Regulatory elements: Conversation of species – finite and tractable

Evolutionary
signatures of cellular processes – connectivity map Dependency Map
3D

Programmable Genome Targeting –

CRISPR GPS
Genome-wide CRISPR Screen

Human cells – unified coordinated to classify Cells and Tissues

Combine single cells with CRISPR Screening to systematically discover cellularpathway

Comprehensive Tools

Programmable Therapeutics –

DNA-directed Chemical synthesis
DNA-encoded Chemical Libraries
Programmable activation in cell type

Healthcare systems –>> Learning systems

SPEAKERS

	Synthetic biology and next-generation diagnostics James Collins, PhD Termeer Professor of Medical Engineering and Science and Professor of Biological Engineering, MIT Broad Institute of Harvard and MIT Wyss Institute LIVE Synthetic Biology – Reprogramming life Design & model network Encode into DNA plasmid Transfer to cell monitor results Potential for Synthetic Gene Biology Paper-based synthetic Biology distribution without refrigeration RNA sensors with Colorimetric output Rapid prototyping: Ebola sensors Key features of Fieldable paper-based system CRISPR-Cas9 Component for Strain Discrimination – NASBA-CRISPR Cleavage Paper-based Diagnostics for the GUT microbiome Paper-based Diagnostics for HPV: Rapid, Inexpensive Sherlock – Nucleic Acid Detection with CRISPR-Cas13a Human Genotyping Using SHERLOCK Single-based gene usong Shrlock
	Cancer Genome and the Cloud Gad A. Getz, PhD Director, Cancer Genome Computational Analysis Group, Broad Institute of Harvard and MIT LIVE – Cancer is a disease of the Genome and epigenome – Life history of a Tumor Drivers: Cancer phenotype Smoking Defect in DNA repair Mutation type: C->T Part 1: Finding Drivers Score genes by number and type of mutations: mutation tally and score of repair 450 genes va 11 genes 33 NEW cancer genes: 4,729 tumors, 21 tumor type, 254 significant genes Gene Catalogue by Tumor type – 2,000 samples needed – to detect 90% Burden clustering Non-coding drivers: Promoter, Insulator 9 significant mutations in Breast cancer gene – promoter Hotspot in FOXA1 is activated through E2F – Estrogene receptor Mutational Signatures Non-negative Matrix Factorization (NMF) posterior distribution of the signatures Homologuos recombination repair pathway BRCA1/2: Signature analyzer: Breast Cancer mutation signatures Mono-alleleic inactivation of BRCA Germline mutation PALB2 PAthogenic mutations in genes RAD51C – the third BRCA Signature 3 is associated with BRCA www.firecloud.org
	Targeting Aggressive Cancers Nanolayers at a Time: A Platform Approach to Engineered Nanomedicine Paula T. Hammond, PhD David H. Koch Professor in Engineering, MIT Head of the Department of Chemical Engineering, MIT Koch Institute, MIT LIVE Layer-by-Layer (LBL) Assembly – The ultimate Nanofab Tool Multilayered, multifunctional LbL Nanoparticles – chemotherapy at the core of a sphere Engineering, Biology and Medicine — to understand activation Incorporate siRNA – a modular design pH-Dependent [6.0 – 7.4] Cell Uptake at Hypoxic Conditions surface induce acid pH avtive Tumor targeting (CD44) – Drug-loaded nanoparticle/PLL Triple Targeting Threat: size, tumor hypoxia, cell receptor A model target: MRP1 protein – Multidrug resistance A tumor treatment study in TNBC subcutaneous model using synergisitc siRNA Combo LbL NanoP’s work KRAS inhibition: NSCLC: Kras siRNA + miRNA miR34a MicroRNA cisplatin naoparticle – Orthotopic KP model: siRNA Second Window NIR Imaging (NIR-II) – deep tissue of Ovarian Cancer Nanoparticle Characterization Ovarian Cancer imaging Charged Assembly a Different way: Electrostatic Self-assembly of Oligopeptide Amphiphiles Peptide Nanoparticles are suitable for Vivo – p53-Deficient Cells Target: MK2 Mediates DNA Damage Repair Small molecules: Not safe not specific
	New chemical engieering approaches to convergence Robert S. Langer, ScD David H. Koch Institute Professor, MIT Koch Institute, MIT LIVE Lysozyme soybean Trypsin inhibitor Alkaline phosphatase Catalase Combinatorial lipid synthesis Next generation LNPs: with novel lipids – potency improvement Nano formulations for Entdothelium – combinatorial generation Nano particle library Current techniques: Electroporation – insert inside the gene – CellSqueeze of the cytoplasm Full transcriptome microarray Applications to Personalized Medicine Injectable chip with combination drug therapy inserted into the Tumor, MIS, Confining region of tumor Conversion : Clinicians and Engineers
	Understanding transcription and splicing heterogeneity in cancer progression Daniel Larson, PhD NIH Stadtman Investigator, Center for Cancer Research Head, Systems Biology of Gene Expression, National Cancer Institute Daniel Larson, NCI – Transcription and Splicing in Heterogeneity in Cancer Progression LIVE TFF1 Transcription in living cells: Estrogene response Transcription occures in bursts: seconds to several hours – regulated over multiple timescale 4oth Anniversary of Splicing high throughput approach for labelling thousands of genes at their endogenous loci SLC2A1 Splicing times andd burst size are highly similar across genes. Strong conservation in Eucaryote ccells Splicing factor mutations emerged in almost all tumor types 3″ SS recognition factor U2AF1 has a missense mutation in the zinc finger domain DNA damage after X-Ray treatment: U2AF1 S34F cells show – cell survive high dose (20 Gy) irradiation, becomes senescent and live >1 month in culture abd secrete interleukin 8 Interleukin 8 Upregulated even before DNA damage – expression and secretion in rare cells IL-8 induces Epithelial-Mesenchymal Transition i primary mamary epithelial cells Stochastic transcription and RNA splicing – IL-8 Secretion
	Computational Models of Cancer Franziska Michor, PhD Professor of Computational Biology, Dana-Farber Cancer Institute Harvard T.H. Chan School of Public Health LIVE Tumor evolve by natural selection Tarceva – approval 2004 – NSCLC – patients with EGRF mutant Effect of dosing:Number of sensitive cells in Two drug concentrations: Sensitive vs Resistant cells Combination Treatment Better parameter estimation: using single cell lineage tracing data microenvironment determinants of Treatment response Determining Optimum radiation schedules in GBM mathematical modeling of treatment response understanding the intratumor heterogeneity based on mouse modeling optimal radiation schedule –>> dose constraints – Ultra fractionated dose vs. Practicality constraints slower proliferation Radiation plus temozolomide: Optimized; time post treatment/percent survival Treatment modalities: Immunotherapy, chemo drugs
	Spherical Nucleic Acids as a Powerful New Platform for Cancer Therapy Chad A. Mirkin, PhD Director, International Institute for Nanotechnology George B. Rathmann Professor of Chemistry, Department of Chemistry, Northwestern University LIVE Next wave of Pharmaceuticals Small molecules’ biologics Nucleic Acids – limitations: Address disease in the Liver The Promise of Therapeutic Oligonucleotides Antisense DNA Spherical Nucleic Acids (SNA) – New way of thinking on DNA and RNA Hybridization Thermodynamics of SNAs SNAs enter cells rapidly and efficiently – over 60 different Cell Types Cy5-labeled SNA SNAs Come in many forms: Micellar SNA, Protein SNAs, Lipoprotein SNAs Late endosome nOT lysosomeow How does cell membrane recognition of SNAs and trigger exocytosis SNAs as Therapeutics: Skin (topical for Psoriasis), Brain (GBM) Immunostimulatory SNAs – activity of IS-SNAs in Vivo Oligonucleitides strands mimicking bacterial DNA or RNA SNA – Vaccines: Antigen presenting cells 3D Architecture of SNAs leads ti enhanced TLP9 Activation – B-cell NF-KB Activation SNAs Vaccines: -In Vivo Testing: retired Tumor growth vs control – inserted inside liposome Advantages SNAs Vaccine vs Standard Formulations vs adjuvant (antigen) SNA TLR-9 Activator Treatmeent vs Linear Oligo (EMT-6 Breast Cancer Model] – it potentiates activity of Anti-PD-1 Antibodies in PD-1 Resistant tumor confers immunity SNA Competitive advantage
	Dissecting the tumor ecosystem with single cell genomics Aviv Regev, PhD Director, Klarman Cell Observatory and Cell Circuits Program, Broad Institute of Harvard and MIT Professor of Biology, Department of Biology, MIT Koch Institute, MIT LIVE – Tumors: A complex cellular Ecosystem How to use Genomic sto study tumors? Option 1: Gene Atlas – single cell genomics can help dissect thie ecosystem – bulk cell Option 2: Tumor Cell Atlas – single cell Single cell RNA-Seq in Precision Medicine pipeline 19 metastasis melanomas: “non-design” design – 4600 cells Malignant or not? DNA or RNA-inferred Micronvironment of the cell – Diverse T cells, Naive, – Tumar infiltrating T cells: Activation-independent variation in exhaustion program across cells cytotoxicity, exhausion, naive RNA-Seq associates T cell clones with their states Cell-types and states in the melanoma ecosystem: single cell signature used to cluster bulk tumors by their microenvironment composition TCGA – Tumors – melanoma vs Cell type specific signature genes inferring cell-cell interactions: Cell type A and Cell type B: Correlation of gene’s expression with inferred proportion of cell type B (bulk samples) CAF expression of chemokines and complement associated with CD8 T cell infiltration Primary Test Stronger control The ecosystem of Malignant Melanoma – 19 malignant cells Treatment naive vs Immunotherapy resistant (ITR) – CD8 cells from ITR sample – intratumor variation How malignant melanocyte affect T-cells? Infiltrated tumor vs exclusion tumor ITR has prognostic value – predicts response to anti-PD1 in Pationts ITR Signatures in malignant and CD8 T cells
	Illuminating biology at the nanoscale and systems scale using single-molecule and super-resolution imaging Xiaowei Zhuang, PhD David B. Arnold Professor of Science, Harvard University Session I: NEW VIEW Xiaowei Zhuang, Harvard University — Single-Cell Transcriptome and Genome Imaging, Science, 2015, PNAS, 2016 LIVE molecular specificity moleculare-scale resolution genome scale throughputspatially-resolved single-cell transcriptome subcellular organization of the transcriptome Spatial organization of transcriptome in tissue Transcriptome Imaging single-molecule FISH (smFISH) [Image 1,2,3,4,, Decoded Image] Error-robust encoding: Hamming code Modified Hamming distance 4 – multiplexed, hydridization Applications: MERFISH imaging of Tissue Spacial organization of cells in Tissues High throughput image-based screening: Barcodes, gene activation/inhibition agents Tracing the 3D conformation of Chromatin Spatial organization of A-B compartments: Transient, Polarized, radial Super resolution of chromatin imaging with Transcriptome imaging

EXPERT PANEL: CONVERGENCE IN HEALTH

	LIVE Cori Bargmann, PhD President of Science, Chan Zuckerberg Initiative Torsten N. Wiesel Professor, The Rockefeller University LIVE – translation of the needs in computational, biology, IT, mathematician, medicine, physics and engineering. BRAIN Initiative at NIH. How to motivate? by a Problem in need for solution
	Marc N. Casper, MBA President and CEO, Thermo Fisher Scientific LIVE – convergence from a tool perspectiveLast 20 years – integration of Biology into the physical sciences, SCREENING AND DIAGNOSTICS
	Victor Dzau, MD President, National Academy of Medicine LIVE As cardiologist: Pace maker Convergence in Research. Funding research does not encourage convergence innovation is killing disease, need to introduce cost effectiveness – economics into the play. Recognition of cost in Precision Medicine: economic model as a tool to consider cost effectiveness, Convergence to include SOcial Sciences and Economics Diagnostics;
	Tyler Jacks, PhD Director, Koch Institute, MIT David H. Koch Professor of Biology, MIT LIVE – Convergence at Koch NIH created few CENTERS for research in Cancer, Brain, Nanotech, focus on Cancer did help the convergence Next step of Convergence: common language, Learning by doing, mechanisms to encourage and continue the convergence Better efficiency: Which Drug to which Patient Early detection and prevention
	Nancy Simonian, MD CEO, Syros Pharmaceuticals, Inc. LIVE – convergence is required to understand the biology of a disease, genomics, computational biology and chemistry is a new approach Cost of Medicines: reibbursement per value vs no concern to value. Innovation t carry premium allowing cost reduction while effciency is been exploled.
	Elias Zerhouni, MD President for Global Research and Development, Sanofi Former Director, NIH LIVE Convergence of multidisciplines is a must for scientific solutions to emerge, horizontal integration Patient Bill of Right Defficiet every year in the US,
	Moderated by: Susan Hockfield, PhD President Emerita, MIT Professor of Neuroscience, MIT Koch Institute, MIT

Read Full Post »

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 17, 2016| Leave a Comment »

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

1:45 p.m. — Leadership in Personalized Medicine Award

Presenter: William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition

Science, Business and Patents: Millenium, Celgenics, and Medicine/Desease – Member of AAAS

co-Chair Cancer Consorcium

Recipient: Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

PM – 1990’s on. How Human Genome at Harvard will start a new center – reach out to the Global community, conference was born. PM as subject of a Global Conference, effirt started with Genzyme, Eric Launder, Broad, Collins at NIH – effort led to Obama Initiative in PM, Duke Medical System.

Challenge: Reimbursement for Genomics diagnosis

PM – P care – by sequencing of Genome – become available commercially inexpensivelly
Genetic component to become part and parcial of Medicine and Patient care

2:15 p.m. — Networking Break

2:45 p.m. — The Data Dilemma: Fulfilling Expectations of Big Data in the Future of Personalized Medicine

There is consensus that the massive amounts of genomic, clinical, claims and other types of data could yield important insights for research and clinical care. But for years, obstacles around technical standards, interoperability, privacy and confidentiality, data security, and consent have been held up as daunting challenges that inevitably slowed progress. During this discussion, a panel of academic and industry experts will discuss their respective organizations’ strategies to obtain and analyze the data, including what has worked and what has not; the programs and processes that have led to the most productive data usage; examples of important knowledge that has been derived from data analysis; and the infrastructure they believe is needed to achieve fulfillment of the potential of big data in personalized medicine nationwide.

Moderator: Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare

How one works with 20 Partners at once?

Paul Bleicher, M.D., Ph.D., CEO, OptumLabs

Data collaboration of 35 Partners – bring value to Medicine, Like Bell Labs
Academics, Hospitals, Physician offices – Constellations – groups of projects
DATA is KEY — Public and Private Partnerships

Christophe G. Lambert, Ph.D., Associate Professor, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico

VA Data, Co-Chair of Informatics, clinical , pharmaceutical stackholders
Focus Groups Patient research Partners – How to automate data
Centralization above nad decentralization, below COntrol mechanism govern all variables: Increase fitness of system vs Personal Control
1984-1998 Bi-Partisan support for Data in HealthCare
Big Data for early detection, prevention, `
AGING, Infectious and Pediatric disease – Investment in these areas

Adam Margolin, Ph.D., Director, Computational Biology, Oregon Health & Science University School of Medicine

Project with Intel – across institutions
consorsium – success ration
data sharing #1 Priority at the National Level
Add value by data sharing, strategic investment in the healh system

Edward J. Stepanski, Ph.D., Chief Operating Officer, Vector Oncology

Propriatory real time reporting to Physicians – systematic – core asset, originally,
Research Group use Warehouse doing Analytics, Tools development linked with clinical data with PRO and studies based on data integretion
Success is more data – PRO data informing clinical data
Defragmenting the care vs drive across town for care several units disaggregated geography vs all deaprtments in one location

3:45 p.m. — Keynote Speaker
“Medicine and the Targeted Marketing Problem”

We live in the golden age of cloud computing and machine learning. The organizing conundrum for the “big data era,” however, is a surprising one — the “targeted marketing problem” (i.e., the ability to better match the right customers to targeted messages). This talk will explore overlaps and similarities between the targeted marketing problem and precision medicine, and how advances in data sciences can be leveraged to create a learning medical system that in turn points to the health care system of the future.

Introduction: Amy Abernethy, M.D., Ph.D., Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Anthony Philippakis, M.D., Ph.D., Cardiologist, BWH, Chief Data Officer, Broad Institute and Partner, GV (Venture Capital)

Learning from Users

Five causes for cardiac death:

MI,
a-Fib
Structural
PE
Aorta dissection

PreventionGenomic Sequencingvalue in Cardiology:

Estonia BioBank – mutation carrier
Familial Hypercholesterolemia – 4 genes involved,
Prediction sudden cardiac death – larger data sets
New Model for Human Subjects Research; DIrect-to-Participant: Potentia Advantages:
cost, scalability, facilitate re-contact, frequent collection,
My Research Legacy: Broad & AHA – Launched November 13, 2016
Quantified Self –>> Quantigied Physical Exam: Face dysformia, Dysarthia, Ataxia,
Identify every patient in the World with this disease

Data sharing: Inverting the Model ; ALL OF US – 1 Million – Precision Medicine with IBM – Mandate to innovate – Diversity: People, Geography, Health Status

Innovation in Genomic data sharing – bring data to researchers

SIX types od data wil be collected: Participant-provided Info, mHealth Data, Consent EMR

DATA Research CoreVanderbuilt, Verily Broad

pharmacogenomics

Launch start ups cost

Open source
Cloud
developers start ups

PLATFORM

GATK – workhorse of genomic data – Launched 4/2016

Partnerships: Amazon, google genomics, microsoft, IBM, Watson,

Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute

Reference Architecture: Design: Single node, small cluster,

4:30 p.m. — Closing Remarks

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_17_Program#sthash.zpTNQYKd.dpuf

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program

Read Full Post »

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 17, 2016| Leave a Comment »

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

7:00 a.m. — Registration and Continental Breakfast

8:00 a.m. — Opening Remarks

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:15 a.m. — Fireside Chat

Moderator: Meg Tirrell, Reporter, CNBC

How did the the Economics changed

Daniel O’Day, CEO, Roche Pharmaceuticals – Joined Roche at 1989

Roche – 60% of investments goes to Cancer with embedded diagnostics, 20-30% of the market
Hypothesis in the Lab starts an innovation – Phase I, Phase II is extension of Phase I – continue understanding of the Biology of the Disease
Treat only patient that will benefit – PM – transformational benefit
Early stage of discovery – protection of IP – work inside ONE company — less of an issur the protection of IP
Diagnostics area – Roche collaborates with other Pharma
Setting infrastructure for testing
Diagnostics and Pharma are coming together – availability of big data – discover and develop with Foundation Medicine – Deep analysis of Molecular Medicine, decide o better hypothesis, do it in shorter time – 2015 – Commercialize the platform around the Globe, One standard for Clinical Trials – in China hard to move Clinical Trials Data out of China –
Harnessing Global Data in Oncology – Clinical Trials
Data accuracy
Genentech, Foundation Medicine and Roche capabilities – FDA
Comprehensive Genomics side – has needs yet to be developed for Payers to participate
Foundation One – 30% more positive Lung Cancers found vs standard of testing
Over simplification is dangerous, technology/diagnostocs/histology/genomics – sequencing ENHANCES not replaces
Data of Phase III – robust genomics profiling: no diagnostics and wrong diagnostics
In the next five years, Cancer immunotherapy, when and how resistance occur.
Blood based assay – Patient journey – fine tuning the Science tissue based sample
Biomarkers: Tumor microenvironment
Diagnostics is not rewarded appropriately, genetics, CMS,
Outcome value for TX and Dx
Mission of Roche will not Change with change of Gov’t, public Sector in the US, FDA – requires being faster a respondent,
” I am optimistic”

Questions from the audience

Democratizing access to sequencing data
accuracy of test results, Oncologist and PCP ordering genomics tests, value added
PM after medicine SOC (biopsy, tissue histology)
Reimbursement: Diagnostics vs drugs

8:45 a.m. — Coverage is King: Identifying the Evidence That Leads to Reimbursement

Many innovators in personalized medicine are unclear on the kinds of evidence that inform the coverage and payment decisions of payers. That lack of clarity can have negative financial consequences for personalized medicine companies with products and services that are on the market but not paid for. During this panel, payer representatives will help define the reimbursement landscape for the field by providing examples of the evidence they consider appropriate for coverage and payment. Confirmed panelists include:

Moderator:Amy M. Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition

What each of the companies does in PM
Targeted therapeutics: 25% are targeted,
Value of Diagnostics

Kristine Bordenave, M.D., Lead Medical Director, Humana

Clinical perspective, how much it cost to patient, clinician, Pharma – both need to be paid,
Population Health, 100% of GDP to go to HealthCare — can’t be
Humana Perspective: How to cover – organized criming: Charges for Testin – several month doen in one day, sharing drugs, expired drugs, repackaged and sold, drugs resold
Independent Research Department: MS, Pharmacists, Statisticians — Looking at the Value of Test in Population context
Large Medicare, Small managed care company, Value-based contracts: working with Pharma – early on at Phase II stage
Testing: genetics, radiographic — 60 gene panel – done by two labs,
Duplication in ordering genetic testing: optometrists, Physical therapist, ordering genetic profiling

Matthew Fontana, M.D., Vice President and Chief Medical Officer, Pharmacy, Health Care Service Corporation

WHY REFERE TO US AS PAYERS – BUSINESS MODEL: MULTIPLE CUSTOMERS MEDICAID, BIG PROVIDERS, MANAGED CARE INDUSTRY
Cost and Revenue
FDA is been pushed to ignore the science (DMD), lack of coordination in HealthCare
Pay for diagnostics if not linked to Therapeutics – morbidity
elaboration of Diagnostics
Accuracy of testing – expensive – misinterpretation

Elaine Jeter, M.D., MolDx Medical Director, Palmetto GBA

Access of Patients – 25 of 50 States are participants in MOlDx — NOT New England States
All molecular assays to register for code specificity – to be able to control appropriate coding – Panel matched to unit of service issue between Genome Profiling and assay
Reimbursement – Lung Cancer – Clinical utility – genomic profiling ONLY IF THE DATA IS IN A REGISTRY — IF PROVED UTILITY AND THE REGISTRY SHOULD BE IN PUBLIC DOMAIN
Analytical minimal standard accepted
Developed Assessment meetings – Labs come to receive guidance – clinical utility information, as a contractor – Central Office allowed PM vs Lab developing tests – assist Lab – pay for service obtain end points
Assays for Prostate Cancer – innovative – high disease demand, define endpoints
Paying premium for FDA approved genetic testing – onlu 2% of molecular assays — 98% are not FDA approved
65,000 molecular tests in the market in the Registry only 10,000, every day 2-3 new molecular assay tests are introduced
By statue, no screening covered by Medicare for Genetic testing – congress need to act upon that – change coverage of Medicare. Memogram and colonoscopy, lung X-ray – are by statue – covered by Medicare

Questions from the Audience

Why premium paid if FDA approved a test?
Screening and early detection

9:45 a.m. — Networking Break

10:15 a.m. — Harvard Business School Case Study Presentation

DNA-editing technologies have been hailed as revolutionary with the possibility to edit out mutations that cause disease. Yet the CRISPR-Cas system is currently locked in a legal dispute between two great research institutions involving, as one journalist put it, “who owns molecular biology.” The CRISPR technology in short raises the broader issue of whether these new techniques should be privately owned or placed in the public domain. The technology also raises serious ethical issues. The case study will serve as the point of departure for our discussion of these issues.

Leader:Richard Hamermesh, D.B.A., Senior Fellow and Former MBA Class of 1961, Professor of Management Practice, Harvard Business School

Ethical issues in the case
Stacks are very high

11:15 a.m. — Keynote Speaker

Introduction:William Chin, M.D., Chief Medical Officer, Executive Vice President, PhRMA
Keynote:Victor Dzau, M.D., President, National Academy of Medicine (ex-IOM) – part of NIH

Global Landscape of PM: Integration into HealthCare — Cost effectiveness
Evidence for PM
better health and well being
high value health care
strong science & technology – 150 papers in JAMA ans NAS
Precision Medicine: patient/public engagement, NGS: omics, biomarkers, collection of clinical & research data, integration of omics, EHR
Challenges: Tests & Therapies
efficacy of PM AFTER actually being used in clinical practice
Evidence of PM efficacy for implementation in Practice
Regulatory and Reimbursement for utility
Reward Value vs cost
Aligning Results: 10% incidence reduction vs 50% incidence reduction
Evidence generation:
Modeling could be used to assess the potential economic impact of PM approaches
Final regulatory & Payment Pathwaysand payer approval
Analytic Validity — clinical validity — economic impact analysis– Assess Clinical Utility
Strength of evidence Low to High
investigational experiment
Assess cost effectiveness: initial experimentation — Economic analysis — provisional approval — validation — final approval
Integration with clinical Practice: Clinician Educatuin, integration pathways
Genomic Medicine:guideline and care pathways — Clinical DSS —
Data infrastructure and sharing: EHR (DIGITize) – genomics – GA4GH
PATIENT/PUBLIC ENGAGEMENT – concern of Privacy and Data Ownership – Fear of discrimination — consent — education of Patients
Future needs: data, National scale learning system, Global collaboration G2GH
Support Data infrastructure
PM – quality, access, cost, improve clinical outcomes, inequality mitigate
PRECISION PUBLIC HEALTH – ZIKA, EBOLA,
GENOMICS and Population Health Action Collaborative
working Groups: Evidence generation

11:45 a.m. — Bag Lunch

12:45 p.m. — Personalizing Care: Strategies for Integrating Personalized Medicine into Health Care

Personalized medicine lacks sufficient literature on how health care providers can integrate personalized medicine into clinical care, which makes it difficult for providers to take advantage of the growing number of personalized medicine products and services now available to them. During this session, panelists who have spearheaded integration efforts will share the strategies they found most useful for speeding the pace of personalized medicine’s adoption in clinical settings. Confirmed panelists include:

Moderator:Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

Awareness & education
Patient empowerment
value recognition
IT and Information Management
ensuring Access to Care: Case if Neuropathy than 15 more visits causing 8 other Patients to be pushed in the queue

Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

Family and Care givers need to understand as well
More Advocacy in Washington

Dax Kurbegov, M.D., Physician Vice President, National Oncology Service Line, Catholic Health Initiatives – CHI (103 Hospitals) and DIgnity ospitals – Community system

Provide speed of service
Permeate piece by piece by each institution, economics – problematic IT infrastructure for Genomics is expensive, centralized system needed
broader beyond Oncology
complex Patients with polypharmacy
If physician needs to write a special note for service , patients are lost in the way for testing
as NGS become accessible in labs — CHI provide infrastructure to LINK Patients with Experts and Labs outside the system

Lincoln Nadauld, M.D., Ph.D., Executive Director of Precision Genomics, Intermountain Healthcare, UT (22 Hospital 107 physicians – Molecular Tumor Board)

Pilot Project approach implemented in 3 hospitals, built lab, implement by Molecular Tumor Board placed on the report
Barriers: getting drug is difficult – mutation exists, drug exists — How to get the drug ordered, approved and shipped
Patients want to know that their oncology is up to date the care is best, Patient advocate for themselves, Patient empowerment
Barriers to PM – Physician compensated better for next line IV chemo vs Targeted Genomic-based therapy
Tumor Board
Get Genomics EARLY not late – it will max the course of treatment
MOST PATIENT CAN’T TRAVEL FOR CARE because it is expensive
Utility and Value asked by Payors, cost saving need be demonstrated not only efficacy vs SOC – reduce cost must be demonstrated

Peter H. O’Donnell, M.D., Assistant Professor of Medicine and Associate Director for Clinical Implementation, Center for Personalized Therapeutics, The University of Chicago

Lab Testing, way to long, system for Physician to look at Genomic data,
If Physician is buying in shared decisions with Patient easier
all tests are bundled and results are presented to PCPs – they love that
Drugs fail because Patients do not take them vs Pharmacogenomics – more likely to help Patients

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program

Read Full Post »

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 16, 2016| Leave a Comment »

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 16

#PMConf

3:15 p.m. — Diagnostics Debate: Regulatory and Reimbursement Hurdles for Personalized Medicine Diagnostics

Nowhere are the regulatory and reimbursement challenges facing personalized medicine more evident than in the diagnostics industry, where the routes to market are often hampered by a lack of clarity regarding the possible changes to the regulatory pathway for laboratory-developed tests, ambiguity regarding the kinds of evidence that justify payment, and the need for large marketing budgets to sell low-cost procedures, all of which impede the development of sophisticated diagnostics with the power to transform medicine.

During this panel discussion, representatives from a diverse range of diagnostics companies, a payer and FDA will identify the most promising strategies to alter the landscape to encourage investment in personalized medicine diagnostic products, including the roles of other stakeholders such as the pharmaceutical industry and integrated health systems.

Moderator: Ronnie Andrews, Founder and Principal, The Bethesda Group

Suzanne Belinson, Ph.D., M.P.H., Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association

Centralized Evidence review – Payers making coverage decisions
Blue Payers: Payers: can modify or use it as such
Value proposition of Evidence Review: Medical Specialties, Payer, Providers, Manufecturer of Diagnostics, Clinical Research
Where is the GAP, in evidence review
engagement with Blue and non Blue, Community based Hospitals
Test utilization – decision is made – withhold a treatment or modification of treatment — at the aggregate level – impact on outcome can be achieved
reduce number of test is a health outcome,
redude numbers of day in Hospital is a Health Outcome
Curate information for Payers to use the information for policy
Prime Therapeutics – PPM of 14 organization — are clients for Evidence Review by Center for Clinical Effectiveness, Blue Cross Blue Shield Association – 36 plans, IT issues, Patient is covered in IL, treatment is givrn in FL, different rules in FL.

Brad Gray, CEO, NanoString

Seattle-based gene expression (emerged in academia), development of diagnosis
IN VITRO DIAGNOSTIC KIT – PREDICTION OF RESPONSE TO BREAST CANCER
Cengene – response to their druv
Medidiation – prospate cancer
Merck – response to Keytruda – multiple indications
Universal asset development: Diagnostics several parameters in ONE test
Policy change is not the focus bur the association of diagnostics with drugs

Alberto Perez, FDA

Michael Pellini, M.D., CEO, Foundation Medicine – had experience with Thermo Fisher Diagnostics
Molecular diagnostics space, information comapny not Lab or Diagnostics
Comprehensive tumor testing – ASSETS:

EXTRACT MOLECULAR information from tissue vs multiple biopsies
COMPEHENSIVE DB OF 1,000 PATIENTS – Genomic Profiling – Rows are cancer type Columns are Published studies providing evidence
Decision Support: MD, Pathologists – Testing Platform submitted to FDA to get regulatory standards
Biliary small tumor

4:30 p.m. — Visions of Value: Evaluating Evidence for Personalized Medicine

The fact that payers, providers, patients, industry representatives and regulators all define value differently makes it difficult for personalized medicine’s champions to contribute to and communicate about the body of evidence supporting the field. Participants in this panel discussion will bring the personalized medicine community closer to an accepted definition of value by identifying common elements in multiple stakeholders’ understanding of the concept.

Moderator: Susan Dentzer, President and CEO, Network for Excellence in Health Innovation

Without Pricing adjustment Access can’t be accomplished
drugs for HPC – patient is not sick enough to qualify for the drug

Donna Cryer, J.D., President and CEO, Global Liver Institute

societal impact of a diagnosis
Development of Value framework, development of he evidence that goes into Value frameworks, Outcomes desireable, Patient generated evidence
Health high functioning citizens and a fibrant Health Care industry
PM PARADIGM accepts Patients factors to be used in algorithm development
Restrictive Formulary for non avarage patients – access at time of need

Michael Sherman, M.D., M.B.A., M.S., Senior Vice President, Chief Medical Officer, Harvard Pilgrim HealthCare

Pay for Service is not connected to Value
Charge the variable cost for testing
DECISION re driven by costs: delivering drug lowering cholesterol to avoid facing expenses of trating CVD
Higher price for success
Care about the total cost of Care
payment for innovations

Peter B. Bach, M.D., M.A.P.P., Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Oncology drugs and Priding to improve the decision making
US and specialty drugs
severe access problems for drugs to patient – colapse because of Pricing
out performing in cost of treatment per patient
Societal equation – drug prices
AMA embrassed Value based Pricing on 11/16/2016
Linking Price of Drug with what the drug does

Randy Barkholder, PhRMA

consolidation Prices for Medicine and for Societal are different
add value to the Healthcare system
Performace and quality to measure value
Drug companies representation and SOcietal values vs HealthCare system value

5:30 p.m. — Elements Café Cocktail Reception

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_16_Program

Read Full Post »

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Posted in 3D Printing for Medical Application, Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 16, 2016| Leave a Comment »

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Reporter: Aviva Lev-Ari, PhD, RN

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 16

#PMConf

1:15 p.m. — Update: Kraft Precision Medicine Accelerator & Trials Challenge Award

An update on the activities of the Kraft Precision Medicine Accelerator and interviews with the winners of Harvard Business School’s “Precision Trials Challenge,” sponsored by the Kraft Precision Medicine Accelerator.

Presenter: Richard Hamermesh, D.B.A., Faculty Co-Chair, Kraft Precision Medicine Accelerator, Harvard Business School
Winner: MatchMiner
- Team Lead: Ethan Cerami, Ph.D., Director, Knowledge Systems Group, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute

17,000 patients now are genome sequenced
Rational clinical trial design
enroll patient n trial
clinical decision support
Trial-Centric Matching vs Patient Centric Matching
Open Source PLATFORM
Clinical Trial Markup Language (CTML)
MatchMiner, Knowledge System, The Hyve

Runner Up: No Patients Left Behind
- Team Lead: Gavin MacBeath, Ph.D., Co-Founder and Senior Vice President, Merrimack Pharmaceuticals

Company brings Drug and biomarker assay match – for patient assignment to Trial
Protein based not genomic based test

Runner Up: iCare for Cancer Patients
- Team Lead: Leylah Drusbosky, Ph.D., Associate Professor of Medicine, University of Florida, Scientific Director, iCare for Cancer Patients

iCare for Cancer Patients
Protein Network Map: Drug interaction and Genomic aberrations
Functional interactions
Predictive SImulation Technology

Computational Biology Model: Proliferation, SUrvival apoptosis

VIrtual Cancer Clinical Trial Simulator – Bring new drugs to the RIGHT patient population: DIsease onhibition score

1:45 p.m. — Keynote Speaker
“Reforming Clinical Trials: How Alternative Trial Designs May Reshape Regulatory Review”

Traditional clinical trial designs are often too cumbersome and expensive to study the efficacy of personalized medicine products and services in sub-populations of patients. Yet there is no consensus on which methods have the most promise to speed trials and lower costs. During her keynote address, Dr. Woodcock will explore which of the latest progressive designs she believes are best suited to demonstrate the efficacy of personalized medicine based on past successes and proposed reforms.

Introduction: Steve BMS
Keynote: Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Not just the trial, but the Development Program
knowledge that underpins the program vs Novel Trial Design
+50% of Trials FAIL at Phase 3 – simulate best and worse scenarios
Cut off points – affect the result of the Human Trial
Outcome measures for disease have never or rarely, been tested
Murphy’s law operate
robust vs fragile design
DEsign – conduct a seamless, adaptive development program
Trade off – for benefits vs burden of Disease – Functionality vs Longevity – give up life for better functionality when aive
More patient enroll or tril goes longer, treatment gets better and Endpoints needs to be revised
heterogenious progression, fast progression
DIsease heterogeniety — REDUCTION by beter Patient selection – more homogenious to reach similar progression
Natural History: rare diseas vs heterogeneous
Progression not known because longitudinal studies are limited or study is not representative
projection of results of trial may be difict: Pharmacodynamic Markers (efficacy) dificult to reproduce
Trial Design: Phase 1,2,3
Alternatives: “Extended Phase 1 COhort” –>> Approval
Endpoint (cancer): Response rate, Progression Free Survival (PFS) Time
Mechanistics hypothesis, natural history data on non responding patients
N-of -1 looking at disease trajectory
Oncology: “basket” trials with biomarker defined targets across histologic diagnoses : NCI “MATCH” trial
Emergencies: EBOLA trial
DOse-finding can be randomized, adaptive,, include placedbo arm
Serious, Rare or Uncommon DIsease wiht Existing Standard of Care (SOC) vs Placebo
Common Diseaase with SOC
Biomarkers: Predictive of Response: Magnitude of the response not Yes or No — Highest Biomarket Cutoff
RWE – Rare WOrld Evidence
Knowledge tht UNDERLIE – biological knowledge
CUrative therappy with PM – promise is there

2:15 p.m. — Fireside Chat

Moderator: Alexander Vadas, Ph.D., Managing Director and Partner, L.E.K. Consulting

Companion Diagnostics

Peer M. Schatz, M.B.A., CEO, QIAGEN (15 years around)

PM and experience
Value chain of PM does not work – Diagnostics is 2% of the HealthCare expenses. Reimbursement by COst of Production
30x smaller then Pharmaceuticals
Standards to evaluate the value of diagnostics
Biomarkers – 60,000 distinctive tests
Benefits of Diagnostics not recognized
HealthCare 2% spent on DIagnostics and Monitoring
Value of information of Molecualr DIagnostics
Lower quality evidence
Reward value of diagnostics – Patients
For LABs diagnostics is a profit looser
Molecular Diagnostics – new, PM is known in 1999 – AMP launched its Journal
Value based Medicine, systems of rewards is to blame
Reimbursement – Diagnostics and regulatory
30 Pharma Partnerships
Industry organization
Biopsy to Microbiome
70% of Cancer care is done at COmmunity Hospitals
Human genomics data doubles annoually
Data needs, 34% in accordance, 70% accordance with diagnosis – CONCORDANCE POOR CROSS GENOMICS OR AXON LABS
PM recognize the value of information DIagnosis, improvemnet in Patient Diagnosis

Reply to interview by Alexander Vadas, Ph.D., Managing Director and Partner, L.E.K. Consulting

Education of Pathologists in Genomic Pathology
Approval of Companion Diagnostics in China requires infrastructure in regulatory interface with each Country
Seamless interaction with Pharma
If tests in Pathology are too expensive, LABS will not be able to be profitable
NGS – Variance – vs a frontline test Designed for Reimbursability and profitaility

2:45 p.m. — Networking Break

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_16_Program

Read Full Post »

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 16, 2016| Leave a Comment »

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 16

#PMConf

Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

7:00 a.m. — Registration and Breakfast

8:00 a.m. — Opening Remarks – [Personalized Medicine = PM]

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
PM offers a more efficient HealthCare: Gov’t, Academia, research, pharma and Patients collaborations = working together
PMC goal – solutions in the field, stacks are high
Corporate sponsors: Genetech-Roache, astellas, Intermountain Precision Medicine

8:05 a.m. — The Personalized Medicine Report

William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition
Five medicines in 2016 are defined as PM
Efficiences in Care by Precision Medicine
Sequencing, molecular medicine, Genomics in all Medical Record

8:15 a.m. — Keynote Speaker

Greg Simon, Executive Director, Cancer Moonshot Task Force
400 people in Washington at the Launch of Moonshot, 7,000 in audio/video attendance around the US
Video by all stackholders
Joe Bidan, today we are more ready than one year ago – ergency of now – a challenge we are not willing to postpone
Example CLL therapeutics today vs 20 years ago
Precision Medicine is the technology & Big Dat aand Science and Survivorship; PM is about the Patient
TASK FORCE on Cancer: added EPA, Council for the Arts, DoD
Double impact – How, Partnerships
VA – many Veterans with Cancers – Sequence effort, Watson-IBM, to review sequences from VA – new partnerships: IBM + VA – Walter Reed Initiative
VA tishue bank with 20 Companies – new Partnership
DoD and VA
Private initiatives on Moonshot topics: American Cancer SOciety – does their own, Foundations, Academia,
Health Systems, several not one — join together Dana Farbers, Sloan Katering
Accessible Medications is very important for Patients
The significance of 9 month to start changing the World

8:45 a.m. — Pioneering Precision: Charting a Course for Cutting-Edge Innovations

Many scientists believe innovations in personalized medicine are poised to yield major breakthroughs in coming years, but not all members of the health care system are clear on which research topics have the most potential. The participants in this panel will identify the most encouraging scientific directions for personalized medicine and point to the most promising topics for future research.

Moderator: Stephen Eck, M.D., Ph.D., Vice President, Oncology Medical Sciences, Astellas Pharma Global Development

Oncology drugs were prescribed by histology no molecular diagnostics
2015 – 25% of FDA approved medicines are PM
In 2016 – PM and molecular diagnostics – needs to be a SYSTEM not disjoint solutions
Value for Price, small indications, cost containment
Pricing treatment if several drugs are at use wihtout knowing the realtive contribution of each

David Altshuler, M.D., Ph.D., Executive Vice President, Global Research and Chief Scientific Officer, Vertex

Prevent and modify the course, Human genetics and somatic genetics in cancer, discovery started with Mandelian, moved to somatic, now use of catelogue for common mutations,
Test existing hypothesis on pathphysiology: LDL and heart disease vs HDL – genetics variance for Heart attack – predictor not modifier
Predicting with Genome in PM, who respond to which medication
New Hypothesis for new Paradigms
Cyctic FIbrosis: Gene found, took a histology based disease CF – to foundational genomics – mutation in gene on cell surface – POTENTIATOR of opening the channel by a small molecule — these small molecule were developed in the last 15 years, follow Patients in Registries – reduction in rate of decline of lung function — Drug – is changing the course of the disease and intervention early
small molecule in combination into cells that have only one copy, in a dish – two medications in Phase II
Personalization is a statement of not ahving yet an effective therapy but it is identification of the Pathway
Common genotype – small groupsidentification
target diseases that will show doubling efficacy, curative therapies, new models: PENETRATION OF LYTHAL DISEASES
Annuity model only in the future the outcome allows measurement – REGISTRIES are very important and need be used for outcomes in the future

Michael Panzara, M.D., Head of Neurology Franchise, WAVE Life Sciences

Synthesis of nucleaic acid focusing on neurology – STEREOCHEMISTRY
modify sulfor – phorphate new modification – mixure of isomeres stereo molecules – systhesize nuclaic acids
design nucleic acids
Pipeline: CNS, MUSCLES, EYE, Liver, Skin, GI
HD – Huntington’s Disease [Mutant HTT] – cognitive decline
WAVE approach: target only the mutant HTT while leaving wild-type intact – disease modifier
Targeted therpy mHTT RNA – transcript of mutant, SNP
Complement activation assay vs HTT transcript – wtHTT: Patients with long CAG repeat associated with T isoform will be selected for trial.
DMD – Exom Skipping,vs Dysfunctional Splicing: Dystrophin (increase production) vs Vinculin

Barbara Weber, M.D., Interim Chief Medical Officer, Neon Therapeutics

Neoantigen biology: Native antigens (targets are expressed in both tumor and normal cells vs Neoantigens (Targets are specific to each Tumor)

Checkpoint inhibitor drug class: Neoantigen-based Therapies may expand ACTIVITY of Checkpoint Inhibitor – Nature 2013

Ipilimumab in melanoma (NEJM 2014
Pembrolizumab in NSCLC, Science 2015
Pembrolizumab in colonorectal cancer, NEJM 2015

NEON: Personalized Neoantigens

personalized CAR-T
personalized Vaccines
Epitope Librart – Epitope selection
NT-001 PM Clinical Trial: combination of Neoantigen Vaccine wiht Checkpoint Inhibitor – PD-1
Monitor Immune response after insertion of neoantigents

9:45 a.m. — Networking Break

10:15 a.m. — Money Talks: The Future of Investment in Personalized Medicinemolecular diagnostics

Innovation requires investment. During this discussion, a panel of diverse investors will illuminate the most promising business opportunities for advancing personalized medicine, focusing on both macro and micro environments while also discussing the barriers to investment and potential solutions for removing them.

Moderator: Edward Winnick, Editor in Chief, GenomeWeb

Beyond Ocology

Alexis Borisy, M.S., Partner, Third Rock Ventures

What excite now – Breakthrough therapies in the RIGHT Patient populations
FOundation Medicine – 1,000 Patients treated with FOundationOne across diagnostics and drug – genomics and disease and therapy in One
New Diagnostics company creation – is very hard, not many, only if it is an extraordinary compelling idea, If FDA approves and the Payers do not endorse
Therapeutics – have a solution, nucleaic based drug, gene editing, Payers are iterested, FDA is interested vs historical standdards, translational medicine – drug will drive diagnostics
Reimbursement, Capital mobilization, new molecular diagnostics, challenges: Technical risk Clinical Risk
Cut off for AstraZeneca vs BMS are different
number tumor cells vs penetration of tumor cells vs infiltration of immune cells
Merck has a different strategy – precise indicator of I/O agents: Single vs. multiple combinations
WHen population of patients is identified well: understand response rate go for 80% response rate inside this population identified
beyond oncology MI and CVD, cardiomyopathy – genetic mutations, familial vs sporadic,
Immunology: Inflammation, innume conditions, understand what is the microtrend in subpopulations
Infectious diseases: organisms given narrow cast antibiotics and trade-offs PM antibiotics is a fundamental challengeresistence to antibiotics
Diagnostics in Cancer – a small fraction vs the cost of Oncology drugs
Longevity drive costs,
Physician diagnostics is critical

Vamil Divan, M.D., M.B.A., Senior Research Analyst, Credit Suisse

BMS is a leader in immunotherapy and Roache as well

Ryan Lindquist, M.B.A., Director, Investment Banking, Leerink Partners

Diagnostics and Precision Medicine
Diagnostics – reimbursement
winners and loosers in Diagnostics
Performance, cost reduction, Payers have rules of engagement
Differentiation of generic drugs: COST OF TREATMENT FO RDRUG $30,000 COST RUNNING TEST $200, Pharma was willing to cut the cost creatively
Drug pricing a point in investing in Biotech
Neuroscience: many drugs are not effication – swab of mouth saliva allows to determine which pshychtropic drug will work for which patient on psych therapies
Data companies with Regulatories
Payers: Kaiser – has Outcome data and cost data
Healthcare system: Payers and Delivery is separate
Patient advocacy on reimbursement is critical and DOctor education on new Diagnostics at Academic Centers

Questions from the audience:

Therapeutics: IP and reimbursement is straight forward
Diagnostics: No IP therefore reimburcement more complex
Data companies
Foundation Medicine: Reimbursement is a challenge – what should the Payer do vs the DIagnostics companies, regulatory, American Pathology Guidelines
Engagement Providers – what is their role?

11:15 a.m. — You + 999,999: How a One Million Person Cohort Can Pave the Way for Personalized Care

Introduction: Paolo Narvaez, Ph.D., Senior Principal Engineer, Director of Engineering, Intel Corporation

1. How to use technology for PM – Intel Life Sciences

Keynote: Eric Dishman, Director, All of Us Research Program, National Institutes of Health

PM Precision vs Personalized Health
All of Us Research Program, National Institutes of Health funded – is PM
Framework Like the Framingham Study
One million Patients, – longitudinal: lifestyle, genes, environmental
HUGE data not a study for one disease, – accelerate Science
Infectious,Neuro, mental, Heart& Lung, Musculo-Skeletal

DIrect Volunteer
Health Provider Org
Enroll & Consent
Surveys Journals
Baseline Measrement
Mission to accelerate Knowledge Turns & Breakthroughs
Participation – Transformational Approach
1,000 vs One million
Diversity: People , geography health Status,
Data Types: Genomics, Claims – Data Access
High schools, community colleges
User-Centered approach
gathering Input
Personas: ready to go, determined, too much Govenment, No time, Suspitious
Platform Innovation Mindset & Process –>> Innovation Fannel
Baseline Physical Evaluation not a Physical Exam
PPI – Participant Provided Information
Mayo Clinic: Biospecimens: Blood and Urine

Research ROADMAP Workshops

Near Term
Mid Term
Long Term

Kind of Attendees: experts network (50 organization, co-funders, advoccy

Biobank – 35Million vials

IT infrafaces–>> security, Enrollement 1-800-

New Eng PM Consortium, Bosotn, MA

12:00 p.m. — Luncheon

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_16_Program

Read Full Post »

LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Posted in Big Data, Biological Networks, Cell Biology, Cell Biology, Signaling & Cell Circuits, Clinical Genomics, Conference Coverage with Social Media, CRISPR/Cas9 & Gene Editing, Disease Biology, Genome Biology, Mutagenesis, RNA Biology, RNA Biology, Cancer and Therapeutics, Scientific & Biotech Conferences: Press Coverage, Uncategorized, Variation in human protein-coding regions, tagged Bioinformatics, Computational Biology/Systems and Bioinformatics, CRISPR, CRISPR Biology • Genome Editing • Gene Drives • DNA Repair • Model and Industrial Organisms • Technology Development • Stem Cells/Cancer • Genome-Wide Screens, CRISPR/Cas and cell & molecular biology, genetic editing, Genomic, screening on September 21, 2016| Leave a Comment »

LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

http://www.discoveryontarget.com/

http://www.discoveryontarget.com/crispr-therapies/

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a

Media Partner of CHI for CHI’s 14^th Annual Discovery on Targettaking place September 19 – 22, 2016 in Boston.

In Attendance, streaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

#BostonDOT16

@BostonDOT

COMMENTS BY Stephen J Williams, PhD

EXPLORING THE VERSATILITY OF CRISPR/Cas9

8:00 Chairperson’s Opening Remarks

TJ Cradick , Ph.D., Head of Genome Editing, CRISPR Therapeutics

@CRISPRTX

8:10 Functional Genomics Using CRISPR-Cas9: Technology and Applications

Neville Sanjana, Ph.D., Core Faculty Member, New York Genome Center and Assistant Professor, Department of Biology & Center for Genomics and Systems Biology, New York University

CRISPR Cas9 is easier to target to multiple genomic loci; RNA specifies DNA targeting; with zinc finger nucleases or TALEEN in the protein specifies DNA targeting

This feature of crisper allows you to make a quick big and cheap array of a GENOME SCALE Crisper Knock out (GeCKO) screening library
How do you scale up the sgRNA for whole genome?; for all genes in RefSeq, identify consitutive exons using RNA-sequencing data from 16 primary human tissue (alot of genes end with ‘gg’) changing the bases on 3’ side negates crisper system but changing on 5’ then crisper works fine
Rank sequences to be specific for target
Cloned array into lentiviral and put in selectable markers
GeCKO displays high consistency betweens reagents for the same gene versus siRNA; GeCKO has high screening sensitivity
98% of genome is noncoding so what about making a library for intronic regions (miRNA, promoter regions?)
So you design the sgRNA library by taking 100kb of gene-adjacent regions
They looked at CUL3; (data will soon be published in Science)
Do a transcription CHIP to verify the lack of binding of transcription factor of interest
Can also target histone marks on promoter and enhancer elements
NYU wants to explore this noncoding screens
sanjanalab.org

@nyuniversity

8:40 Therapeutic Gene Editing With CRISPR/Cas9

TJ Cradick , Ph.D., Head of Genome Editing, CRISPR Therapeutics

NEHJ is down and dirty repair of single nonhomologous end but when have two breaks the NEHJ repair can introduce the inversions or deletions

High-throughput screens are fine but can limit your view of genomic context; genome searches pick unique sites so use bioinformatic programs to design specific guide Rna
Bioinformatic directed, genome wide, functional screens
Compared COSMID and CCTOP; 320 COSMID off-target sites, 333 CCtop off target
Young lab GUIDESeq program genome wide assay useful to design guides
If shorten guide may improve specificity; also sometime better sensitivity if lengthen guide

Manufacturing of autologous gene corrected product ex vivo gene correction (Vertex, Bayer, are partners in this)

They need to use a clones from multiple microarrays before using the GUidESeq but GUIDEseq is better for REMOVING the off targets than actually producing the sgRNA library you want (seems the methods for library development are not fully advanced to do this)

The score sometimes for the sgRNA design programs do not always give the best result because some sgRNAs are genome context dependent

9:10 Towards Combinatorial Drug Discovery: Mining Heterogeneous Phenotypes from Large Scale RNAi/Drug Perturbations

Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

Bioinformatics in CRISPR screens: they looked at image analysis of light microscopy of breast cancer cells and looked for phenotypic changes

Then they modeled in a small pilot and then used the algorithm for 20,000 images (made morphometric measurements)
Can formulate training statistical algorithms to make a decision tree how you classify data points
Although their algorithms worked well there was also human input from scientists

Aggregate ranking of hits programs available on web like LINKS

@MDAndersonNews

10:25 CRISPR in Stem Cell Models of Eye Disease

Alexander Bassuk, M.D., Ph.D., Associate Professor of Pediatrics, Department of Molecular and Cellular Biology, University of Iowa

Blind athlete Michael Stone, biathlete, had eye disease since teenager helped fund and start the clinical trial for Starbardt disease; had one bad copy of ABCA4, heterozygous (inheritable in Ahkenazi Jewish) – a recessive inheritable mutation with juvenile macular degeneration

Also had another male in family with disease but he had another mutation in the RPGR gene
December 2015 paper Precision Medicine: Genetic Repair of retinitis pigmentosa in patient derived stem cells
They were able to correct the iPSCs in the RPGR gene derived from patient however low efficiency of repair, scarless repair, leaves changes in DNA, need clinical grade iPSCs, and need a humanized model of RPGR

@uiowa

10:55 CRISPR in Mouse Models of Eye Disease

Vinit Mahajan, M.D., Ph.D., Assistant Professor of Ophthalmology and Visual Sciences, University of Iowa College of Medicine

degeneration of the retina will see brown spots, the macula will often be preserved but retinal cells damaged but with RPGR have problems with peripheral vision, retinitis pigmentosa get tunnel vision with no peripheral vision (a mouse model of PDE6 Knockout recapitulates this phenotype)
the PDE6 is linked to the rhodopsin GTP pathway
rd1 -/- mouse has something that looks like retinal pigmentosa; has mutant PDE6; is actually a nonsense mutation in rd1 so they tried a crisper to fix in mice
with crisper fix of rd1 nonsense mutation the optic nerve looked comparible to normal and the retina structure restored
photoreceptors layers- some recovery but not complete
sequence results show the DNA is a mosaic so not correcting 100% but only 35% but stil leads to a phenotypic recovery; NHEJ was about 12% to 25% with large deletions
histology is restored in crspr repaired mice
CRSPR off target effects: WGS and analyze for variants SNV/indels, also looked at on target and off target regions; there were no off target SNVs indels while variants that did not pass quality control screening not a single SNV
Rhodopsin mutation accounts for a large % of patients (RhoD190N)
injection of gene therapy vectors: AAV vector carrying CRSPR and cas9 repair templates

CAPN mouse models

family in Iowa have dominant mutation in CAPN5; retinal degenerates
used CRSPR to generate mouse model with mutation in CAPN5 similar to family mutation
compared to other transgenic methods CRSPR is faster to produce a mouse model

To Follow LIVE CONFERENCE COVERAGE PLEASE FOLLOW ON TWITTER USING

Meeting #: #BostonDOT16

Meeting @: @BostonDOT

Overall good meeting #s:

#personalizedmedicine

#innovation

#cancer

#immunology

#immunooncology

#pharmanews

#CRSPR

#geneediting

#crisper

#biotech

AND FOLLOW these @

@pharma_BI

@AVIVA_1950

@BiotechNews

@CHI

@FierceBiotech

Read Full Post »

LPBI Group’s Channels for e-Marketing of Biotech Conferences involve PreConference, During the Conference, Post Conference Tasks

Posted in Conference Coverage with Social Media, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Scientific & Biotech Conferences: Press Coverage on August 18, 2016| Leave a Comment »

LPBI Group’s Channels for e-Marketing of Biotech Conferences involve PreConference, During the Conference, Post Conference tasks, they are:

Author: Aviva Lev-Ari, PhD, RN

UPDATED on 4/5/2018

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018

Channels for e-Marketing of Biotech Conferences

Our Journal +1,031,000 eReaders

http://pharmaceuticalintelligence.com

Aviva’s – +6000 BIOTECH followers on LinkedIn

http://www.linkedin.com/in/avivalevari

LPBI Group’s FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

LPBI Group’s Twitter Account

http://twitter.com/pharma_BI

Aviva Manages three Groups on LinkedIn

LPBI Group’s Company’s Page on LinedIn

https://www.linkedin.com/company/9325543?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A9325543%2Cidx%3A1-1-1%2CtarId%3A1439226813927%2Ctas%3ALeaders%20in%20Pharmaceutica

Tasks done PreConference, During the Conference, Post Conference include:

What Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston can provide Conference Organizers ?

Pre-Conference

Co-marketing of Conferences six month prior to Conference date
Conference Presentation Coverage in Real Time for Scientific Media and Business Media
Conference Presentation Content is published in the Open Access Online Scientific Journal
Social media posting (Twitter and LinkedIn groups) once a month before the event
Pre-conference blog posting of the event
Conference listing/web banner on our website homepage
E-blast to our membership/viewership (with Conference Organizer’s discount code) regarding their conference at a preplanned Time Table presented to us.

During conference

Each Presentation following publication in the Journal is posted on Social media
Generation of electronic Conference Proceedings [LPBI’s e-Proceedings]
“LPBI’s e-Proceedings on DVD” made available for sale by Conference Organizers.
PR Campaign for a Conference event include the following:
Publish the Event in the Journal, options for re-blogging — Using a message provided by the Event Organizer
Connect the Event Announcement to Facebook, Twitter and LPBI’s 56 Groups on LinkedIn — with repeats
Targeted e-mails to potential Speakers and potential Attendees in Aviva’s 6,000 LinkedIn first level connections in Biotech
Per Conference Organizer’s specification of locations, industries and function in the organization message broadcasting to batches of 100 e-mails at a time.
Option to Publish a JOINT Announcement, including the message provided by the Conference Organizers and a message by Leaders of Pharmaceutical Business Intelligence (LPBI) Group, involve private advertisement in channels

Post Conference

Analysis of journal engagement of posts for each talk covered
Social media analysis of conference including Twitter Analysis of meeting including
Twitter engagement statistics of conference
TweetReach analysis of live tweets from the conference
WordCloud of all tweets to identify most engaged and tweeted topics
Post-conference blog posting/report/summary of the event
Twitter and web engagement statistics of live posts and tweets from conference talks
e-Proceeding of the Conference shared with Conference Organizers for their dissemination to all attendees

Read Full Post »

Individualizing Medicine Conference, October 5-6, 2016, Rochester, MN, Hosted by Mayo Clinic Center for Individualized Medicine

Posted in Conference Coverage with Social Media, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on July 14, 2016| Leave a Comment »

Individualizing Medicine Conference, October 5-6, 2016, Rochester, MN, Hosted by Mayo Clinic Center for Individualized Medicine, Supported by the Satter Foundation held at MAYO CIVIC CENTER 30 Civic Center Drive SE, Rochester, MN

Reporter: Aviva Lev-Ari, PhD, RN

Individualizing Medicine 2016: Advancing Care Through Genomics focuses on how to translate the promise of genomic medicine to your practice. Expert speakers, focused breakout sessions, case studies and a poster session provide opportunities to discover and discuss emerging topics in applied genomics.

REGISTRATION

http://individualizingmedicineconference.mayo.edu/

WEDNESDAY, OCTOBER 5, 2016

REGISTRATION INFORMATION

7:00 AMRegistration Desk Opens, Continental Breakfast Available
8:00 AM –8:30 AMIntroductions, Welcome, Tour of conference app
Cathy Wurzer, Minnesota Public Radio (Moderator)
Keith Stewart, M.B., Ch.B., Mayo Clinic
8:30 AM –9:15 AMShaping the Future of Precision Oncology and the Role of the Patient
Kathy Giusti, M.B.A., Multiple Myeloma Research Foundation
9:15 AM –10:00 AMTowards Precision Medicine
Euan A. Ashley, M.R.C.P., D.Phil., Stanford
10:00 AM –10:30 AMBreak with Refreshments
10:30 AM –11:15 AMImproving Outcomes Through Clinical Implementation of Pharmacogenetics
Julie A. Johnson, Pharm.D., University of Florida College of Pharmacy
11:15 AM –12:00 PMTitle To Be Announced
Kathy Hudson, Ph.D., National Institutes of Health (NIH)
12:00 PM –1:00 PMLunch & Presentation
Teri Manolio, M.D., Ph.D., National Human Genome Research Institute, National Institutes of Health
1:00 PM –2:30 PMConcurrent Session 1A Pharmacogenomics in Your Practice
EXPAND
1:00 PM –2:30 PMConcurrent Session 1B The New Frontier – Next Generation Sequencing Based Microbial Diagnostics
EXPAND
1:00 PM –2:30 PMConcurrent Session 1C Novel Genetic Applications with Potential to Transform Healthcare
EXPAND
1:00 PM –2:30 PMConcurrent Session 1D To Be Announced
2:30 PM –2:45 PMBreak with Refreshments
2:45 PM –4:15 PMConcurrent Session 2A Utility of Genetic Testing: Promises and Pitfalls
EXPAND
2:45 PM –4:15 PMConcurrent Session 2B Early Career Investigators in Precision MedicineSupported by the Brandt Family Scholars Fund
EXPAND
2:45 PM –4:15 PMConcurrent Session 2C Functional Studies to Disambiguate Variants of Uncertain Significance in Clinical Testing
EXPAND
2:45 PM –4:15 PMConcurrent Session 2D Pharmacogenomics Guidelines: International and US Perspectives
EXPAND
4:15 PM –4:30 PMBreak
4:30 PM –5:15 PMTo Use or Not to Use: Clinical Application of Genetic Risk Scores in Age-Related Macular Degeneration
Jonathan L. Haines, Ph.D., Case Western Reserve University
5:15 PM –7:15 PMPoster/Welcome Reception, Light Hors d’ Oeuvres and Beverages Available

THURSDAY, OCTOBER 6, 2016

REGISTRATION INFORMATION

7:00 AMRegistration Desk Opens, Continental Breakfast Available
8:00 AM –8:15 AMWelcome
8:15 AM –9:00 AMThe 100,000 Genomes Project
Mark Caulfield, FMedSci, Genomics England
9:00 AM –9:45 AMGenomes, Autism, and More Genomes
Stephen W. Scherer, Ph.D., D.Sc., University of Toronto McLaughlin Centre & Centre for Applied Genomics at SickKids
9:45 AM –10:15 AMBreak with Refreshments
10:15 AM –11:45 AMConcurrent Session 3A Clinical Genomics Management: From the Patient Perspective
EXPAND
10:15 AM –11:45 AMConcurrent Session 3B Applying Pharmacogenomics: Changing Practice, Changing Lives
EXPAND
10:15 AM –11:45 AMConcurrent Session 3C Transforming Patient Care with Microbiome Research
EXPAND
10:15 AM –11:45 AMConcurrent Session 3D Advances in Genomic Laboratory Medicine
EXPAND
11:45 AM –12:45 PMLunch
12:45 PM –2:15 PMConcurrent Session 4A Genomic Case Review with the Experts
EXPAND
12:45 PM –2:15 PMConcurrent Session 4B Predictive and Consumer Genomics
EXPAND
12:45 PM –2:15 PMConcurrent Session 4C Cancer and Precision Medicine
EXPAND
12:45 PM –2:15 PMConcurrent Session 4D Epigenomics to Therapy: Emerging Agents
EXPAND
2:15 PM –2:30 PMBreak with Refreshments
2:30 PM –3:15 PMMarshall Summar, M.D.
3:15 PM –4:00 PMSystems Medicine and P4 Medicine: Transforming Healthcare Through Wellness
LeRoy Hood, M.D., Ph.D.
4:00 PM –4:45 PMConsumer Genomics Panel Discussion

LeRoy Hood, M.D., Ph.D.
Justin Kao
Jill Hagenkord, M.D.
Additional Panel Members to be Announced
4:45 PM –5:00 PMClosing/Summary
Stay for our Friday Workshops! Click here for more information.

FRIDAY, OCTOBER 7, 2016

REGISTRATION INFORMATION

8:00 AM –5:00 PMGeneticon Upper Midwest Clinical Genetics
7:00 AM –8:00 AMContinental Breakfast
7:00 AM –8:00 AMEpigenomics and Microbiome Poster Session
Click here for abstract submission information.
8:00 AM –12:30 PMWorkshop Sessions with a Break
8:00 AM –12:30 PMBio-Marker Discovery TIGER-Bio: The Integrated Genome-analysis Enabled Response Biomarker Program
EXPAND
8:00 AM –12:30 PMEpigenomics Epigenomics: Bridging the Translational Gap
8:00 AM –12:30 PMMicrobiome All You Need Is Bugs
EXPAND
8:00 AM –12:30 PMPharmacogenomics (PGx) Applying PGx with the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Work Group (DPWG)

SOURCE

http://individualizingmedicineconference.mayo.edu/schedule/

http://individualizingmedicineconference.mayo.edu/

Read Full Post »

« Newer Posts - Older Posts »

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Archive for the ‘Scientific & Biotech Conferences: Press Coverage’ Category

30 Years of Convergence

Comprehensive views

Comprehensive Tools

Follow Blog via Email

Recent Posts

Archives

Categories

Meta

Archive for the ‘Scientific & Biotech Conferences: Press Coverage’ Category

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in

REAL TIME

Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017

Forthcoming SEVEN e-Books in 2017 AND Eight e-Books on Amazon.com

Biggest Voices in Cardiovascular Care

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

Monday, May 1, 2017

Opening Remarks Christopher Coburn

Share this:

Like this:

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Summer Symposium 2017

@kochinstitute #KIsymposium @Pharma_BI @AVIVA1950

INTRODUCTORY REMARKS

KEYNOTE SPEAKER

30 Years of Convergence

Comprehensive views

Comprehensive Tools

SPEAKERS

Synthetic biology and next-generation diagnostics

Cancer Genome and the Cloud

Targeting Aggressive Cancers Nanolayers at a Time: A Platform Approach to Engineered Nanomedicine

New chemical engieering approaches to convergence

Current techniques:

Understanding transcription and splicing heterogeneity in cancer progression

Daniel Larson, NCI – Transcription and Splicing in Heterogeneity in Cancer Progression

Computational Models of Cancer

Spherical Nucleic Acids as a Powerful New Platform for Cancer Therapy

Dissecting the tumor ecosystem with single cell genomics

Illuminating biology at the nanoscale and systems scale using single-molecule and super-resolution imaging

Session I: NEW VIEW

Xiaowei Zhuang, Harvard University — Single-Cell Transcriptome and Genome Imaging,

EXPERT PANEL: CONVERGENCE IN HEALTH

Moderated by:

Share this:

Like this:

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

November 17

Share this:

Like this:

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

November 17

Share this:

Like this:

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

November 16

Share this:

Like this:

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

November 16

Share this:

Like this:

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

November 16

Share this:

Like this:

LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a

Media Partner of CHI for CHI’s 14th Annual Discovery on Targettaking place September 19 – 22, 2016 in Boston.

In Attendance, streaming LIVE using Social Media

#BostonDOT16

@BostonDOT

COMMENTS BY Stephen J Williams, PhD

Media Partner of CHI for CHI’s 14^th Annual Discovery on Targettaking place September 19 – 22, 2016 in Boston.